28 MALE GROOMING
This effect was observed in 85% of the volunteers (Fig 3).
Subjective evaluation
The subjective evaluation was examined with the assessment of performance reported by volunteers using a self- evaluation questionnaire filled out after 3, 6 and 8 months of use. The questionnaire contained the following closed questions: Hair loss stabilised? Hair loss stopped? Anti-hair loss product? Hair denser? Hair thicker? Hair more resistant? Scalp better covered by hair? Regrowth of small hairs? Possible answers were: disagree, mostly disagree, mostly agree or agree. At the end of the study, two additional questions were asked to the subjects: l Overall, are you satisfied with this product? l If possible, would you continue using this product?
Hair loss
In the conditions of this study, after 3 months of use, the lotion containing the azalea-isolated yeast active at 0.3% stabilised hair loss in 91% of the volunteers and stopped it in 68% of them. After 6 and 8 months of treatment, all volunteers reported that hair loss was stabilised and stopped in 86% of them after 6 months and in 90% after 8 months. The product was therefore considered to be anti-hair loss by more than 80% of volunteers after 6 months and by 90% of the panel after 8 months of treatment (Fig 4).
Hair quality
In the conditions of this study, the lotion containing the yeast active at 0.3% was generally perceived as positive and very effective by volunteers from 3 months of use and also after 8 months of use, because hairs were perceived as: l Denser by 90% of the volunteers; l Thicker by 85%; l More resistant by 95% of them (Fig 5).
Regrowth of hair
In the conditions of this study, after 3 months of use, the lotion containing the yeast active at 0.3% resulted in better hair coverage of the scalp for 64% of the subjects.
After 6 months of use, the same lotion
was reported to result in regrowth of small hairs by 59% of subjects and better hair coverage was reported by 64% of them. After 8 months of treatment, 85% of the volunteers reported that their scalp was better covered and 80% reported regrowth of small hairs (Fig 6). Finally, 100% of the subjects answered to the additional questions by stating that the product was satisfying and that they desired to continue using it.
PERSONAL CARE ASIA PACIFIC 100 n 3 months n 6 months n 8 months
80
85 60 64 40 64 59 45 20
80
0 Scalp better covered by hair Regrowth of small hairs
Figure 6: Self-evaluation of improved regrowth of hair after 3, 6 and 8 months of twice daily application of the azalea-isolated yeast active formulated at 0.3% in a lotion.
Conclusion With Hairgenyl, Silab offers an outstanding natural solution for two main reasons. Firstly, it has been developed and sustained with robust and valuable efficacy modelling studies. It acts at the core of hair follicle biology by managing the molecular anomalies of androgenetic alopecia, thereby reactivating hair growth. It corrects deregulations of signalling molecules and epigenetics and also stimulates mitochondrial dynamics. Secondly, only 0.3% of the product
formulated in a lotion provided extremely satisfying results in volunteers. Indeed, the azalea-isolated yeast active is proven to promote the regrowth of the hair. After 8 months of twice daily application by a group of Caucasian men with slight to moderate androgenetic alopecia, the active formulated at 0.3% in a lotion: l Increased hair density and the proportion of hair in the growth phase (anagen);
l Limited hair loss. An evaluation of product performance by volunteers has confirmed its efficacy: all the volunteers noted that it considerably reduced hair loss and the vast majority of them reported that their hair was thicker, more resistant and that their scalp was more densely covered. At the end of the study, all volunteers wished to continue using the yeast active. Hairgenyl is an active ingredient rich in biopeptides with low molecular weight. It is obtained from the yeast Pichia minuta, isolated from the flowers of azalea Rhododendron indicum. This yeast is manufactured in Silab’s production unit dedicated to biotechnologies which ensures a complete production and traceability control. The active ingredient is
the result of a non-denaturing production process, highly concentrated in a preservative-free powder form (recommended amount: 0.05 to 0.5%), compliant with global cosmetic regulations (Europe, United States, Japan and China). By regaining density of the hair,
Hairgenyl is the strategy of choice for anti- loss and regrowth actions, thereby limiting baldness.
PC
References 1 Han S-H, Byun J-W, Lee W-S. Quality of Life Assessment in Male Patients with Androgenetic Alopecia: Result of a Prospective, Multicenter Study. Annals of Dermatology 2012; 24: 311-318.
2 Avital YS, Morvay M, Gaaland M, Kemny L. Study of the International Epidemiology of Androgenetic Alopecia in Young Caucasian Men Using Photographs From the Internet. Indian Journal of Dermatology 2014; 60, 1-8.
3 Cranwell W, Sinclair R. Male Androgenetic Alopecia. Endotext [Internet], South Dartmouth (MA) (2000-2016) ;
4 Mirmirani P. Age-related hair changes in men: Mechanisms and management of alopecia and graying. Maturitas 2015 ;80 : 58-62.
5 Pierard-Franchimont C, Pierard GE. Les cheveux et leur environment [Hair and its evnironment]. Revue Medicale de Liège 2015; 70: 70-72.
6 Cranwell, Sinclair R. Male Androgenetic Alopecia. Endotext [Internet], South Dartmouth (MA) (2000-2016)
7 Jain R, De-Eknamkul W. Potential targets in the discovery of new hair growth promoters for androgenic alopecia. Expert Opinion on Therapeutic Targets 2014; 18: 787-806
8 Trüeb RM. Molecular mechanisms of androgenetic alopecia. Experimental Gerontology 2002; 37: 981-990
November 2017
Pooled ‘agree’ and ‘mostly agree’ responses (%)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96
